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Typically, many cell culture-derived viral vaccines are being produced in batch processes. However, with
increasing demands of a growing world population for potent, safe and affordable vaccines, manufacturing
technologies need to be further optimized. In particular, the establishment of two-stage bioreactors appears as an
interesting option for continuous production of viral vaccines. In these systems cell growth and virus propagation
are being performed in separated vessels [1], which make them suitable for production of lytic viruses, such as
influenza and Modified Vaccinia Ankara virus (MVA). MVA virus has received much clinical attention, because it
is as a promising vector candidate in gene therapy, and can also be used as a platform for expression of
recombinant viral antigens including influenza and other viruses [2]. Both influenza and MVA viruses have been
successfully propagated at high yields in batch culture using non-aggregated avian suspension cells [3,4]. To
further optimize the productivity in vaccine manufacturing, semi-continuous or ever continuous production systems
could be considered. However, a serious drawback for influenza virus production (and many other viruses) is the
generation of defective interfering particles (DIPs), known as “von Magnus effect”. This causes oscillations in virus
levels and results in low yields [1]. For MVA production, a large DNA virus, this effect has not yet been described.
Therefore, in this work, first a scale-down approach of the two-stage bioreactor system using semi-continuous
cultivations will be addressed and compared with previous influenza virus experiments [1]. Secondly, the
production of MVA virus in two-stage semi-continuous and continuous bioreactors is explored. Finally, the
compatibility of the continuous harvests with requirements in downstream processing will be discussed for a direct
integration of the continuous mode into the overall production process.
A small scale semi-continuous two-stage cultivation system (100 mL-scale, two shaker flasks, SSC) was
established as an approximation to a real continuous bioreactor (1 L-scale, two-stage stirred tank bioreactor, TSB)
to facilitate process screening [5]. The SSC system was used to produce influenza virus strain A/PR/8/34 (RKI)
[1], the virus strains MVA-CR19, MVA-CR19.GFP, and the duck cell line AGE1.CR.pIX (the latter three from
ProBioGen, Berlin). Furthermore, one continuous cultivation with the TSB set-up for production of MVA-CR19
virus was carried out.
Production in the SSC system resulted in steady-state concentrations of cells with influenza virus titers that
reflected the oscillating dynamics obtained previously with the TSB system [1]. In contrast, the scale-down of MVA
virus production resulted in stable titers of MVA-CR19 virus for over 18 days. PCR analysis of the MVA-CR19.GFP
virus showed stable maintenance of the recombinant transgene without deletion of the GFP insertion cassette
after 14 days of culture. The continuous experiment with the TSB system and the MVA-CR19 virus showed similar
virus titers to those observed in the SSC system and suggested the absence of the “von Magnus effect” over 18
days.
Overall, small scale semi-continuous cultivation was successfully established as a fast and efficient tool for
screening purposes. MVA can be produced in continuous two-stage bioreactor systems for at least 18 days
without reduction of virus yield due to the absence of DIP formation. Therefore, in the future, this system may be
interesting for continuous production of recombinant MVA-based vaccines and gene therapy vectors.
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